Overview

Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP

Status:
Not yet recruiting

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Disc Medicine, Inc